ELOVL3 Inhibitors

ELOVL3 inhibitors primarily include compounds that target lipid metabolism pathways, indirectly influencing the activity of ELOVL3. ELOVL3 is integral in the elongation of very long-chain fatty acids, a process crucial for maintaining proper cellular function, especially in skin and adipose tissue. The inhibition of ELOVL3 can potentially be achieved either by directly targeting the enzyme or by influencing upstream or downstream processes in fatty acid metabolism. The majority of the compounds listed, such as Triacsin C, Cerulenin, and C75, function by inhibiting enzymes involved in fatty acid synthesis or modification, thereby affecting the substrate availability for ELOVL3. For instance, Triacsin C inhibits long-chain acyl-CoA synthetases, crucial for fatty acid activation, indirectly impacting the availability of substrates necessary for ELOVL3's elongation process. Cerulenin and C75, as fatty acid synthase inhibitors, reduce the overall pool of fatty acids available for elongation. On the other hand, compounds like Thiazolidinediones, Statins (e.g., Simvastatin, Lovastatin, Atorvastatin), and fibrates (e.g., Fenofibrate) modulate lipid metabolism at a more systemic level. Thiazolidinediones, commonly used in diabetes management, influence lipid profiles by modulating insulin sensitivity and fatty acid storage, which can indirectly affect ELOVL3's activity. Statins, known for their cholesterol-lowering effects, impact cholesterol biosynthesis and, as a result, have downstream effects on various aspects of lipid metabolism, potentially influencing ELOVL3 activity. Fibrates, through activation of PPARα, alter the expression of genes involved in lipid metabolism, thereby indirectly impacting ELOVL3.